Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
Ingrid A MayerFengmin ZhaoCarlos L ArteagaWilliam Fraser SymmansBen Ho ParkBrian L BurnetteAmye J TevaarwerkSofia F GarciaKaren Lisa SmithDella F MakowerMargaret BlockKimberly A MorleyChirag R JaniCraig MescherShabana J DewaniBernard TawfikLisa E FlaumErica L MayerWilliam M SikovEve T RodlerLynne I WagnerAngela M DeMicheleJoseph A SparanoAntonio C WolffKathy D MillerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Platinum agents do not improve outcomes in patients with basal subtype TNBC RD post-NAC and are associated with more severe toxicity when compared with capecitabine. Participants had a lower than expected 3-year iDFS regardless of study treatment, highlighting the need for better therapies in this high-risk population.
Keyphrases
- phase iii
- neoadjuvant chemotherapy
- locally advanced
- open label
- clinical trial
- double blind
- placebo controlled
- phase ii
- rectal cancer
- lymph node
- phase ii study
- sentinel lymph node
- squamous cell carcinoma
- radiation therapy
- patients undergoing
- randomized controlled trial
- adipose tissue
- type diabetes
- combination therapy
- smoking cessation
- metastatic breast cancer